RON COHEN, M.D.
Osteopathic Medicine at Harriman Rd, Irvington On Hudson, NY
License number
New York 161004
Category
Osteopathic Medicine
Type
Internal Medicine
Address
Address
2
246 Harriman Rd, Irvington On Hudson, NY 10533
15 Skyline Dr, Hawthorne, NY 10532
15 Skyline Dr, Hawthorne, NY 10532
Phone
(800) 555-1212
(914) 347-4300
(914) 347-4462 (Fax)
(914) 347-4300
(914) 347-4462 (Fax)
Personal information
See more information about RON COHEN at radaris.comName
Address
Phone
370 E 76Th St APT C902, New York, NY 10021
3 Links Ct, Huntington, NY 11743
400 Community Dr, Manhasset, NY 11030
400 E 84Th St APT 15D, New York, NY 10028
56 Rowley St, Rochester, NY 14607
Organization information
See more information about RON COHEN at bizstanding.comRon Cohen MD
246 Harriman Rd, Irvington, NY 10533
Categories:
Internal Medicine Physicians & Surgeons
Phone:
(917) 757-9896 (Phone)
Professional information
Dr. Ron Cohen, Irvington NY - MD (Doctor of Medicine)
Specialties:
Internal Medicine
Address:
246 Harriman Rd, Irvington 10533
(800) 555-1212 (Phone)
(800) 555-1212 (Phone)
Certifications:
Internal Medicine, 1984
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Columbia Univ Coll Of Physicians and Surgeons
Graduated: 1981
University Of Virginia Medical Center
Columbia Univ Coll Of Physicians and Surgeons
Graduated: 1981
University Of Virginia Medical Center
Methods Of Using Sustained Release Aminopyridine Compositions
US Patent:
2012016, Jun 28, 2012
Filed:
Mar 2, 2012
Appl. No.:
13/410388
Inventors:
Andrew R. Blight - Mahopac NY, US
Lawrence Maranucci - White Plains NY, US
Ron Cohen - Irvington NY, US
Lawrence Maranucci - White Plains NY, US
Ron Cohen - Irvington NY, US
International Classification:
A61K 49/00, A61P 25/00, A61P 21/00, A61K 31/4409
US Classification:
424 92, 514352
Abstract:
A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition.
Sustained Release Aminopyridine Composition
US Patent:
8007826, Aug 30, 2011
Filed:
Dec 13, 2004
Appl. No.:
11/010828
Inventors:
Andrew R. Blight - Mahopac NY, US
Ron Cohen - Irvington NY, US
Ron Cohen - Irvington NY, US
Assignee:
Acorda Therapeutics, Inc. - Hawthorne NY
International Classification:
A61K 31/44, A61K 9/22
US Classification:
424468, 514352
Abstract:
A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.
Method Of Using Sustained Release Aminopyridine Compositions
US Patent:
8354437, Jan 15, 2013
Filed:
Apr 8, 2005
Appl. No.:
11/102559
Inventors:
Andrew R. Blight - Mahopac NY, US
Ron Cohen - Irvington NY, US
Ron Cohen - Irvington NY, US
Assignee:
Acorda Therapeutics, Inc. - Ardsley NY
International Classification:
A61K 31/44, A61K 9/22
US Classification:
514352, 514903, 514965, 424468
Abstract:
A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition.
Methods Of Using Sustained Release Aminopyridine Compositions
US Patent:
2014003, Feb 6, 2014
Filed:
Mar 14, 2013
Appl. No.:
13/829221
Inventors:
Acorda Therapeutics, Inc. - , US
Ron Cohen - Irvington NY, US
Ron Cohen - Irvington NY, US
Assignee:
Acorda Therapeutics, Inc. - Ardsley NY
International Classification:
A61K 9/20, A61K 31/4409
US Classification:
514352
Abstract:
A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition.
Sustained Release Aminopyridine Composition
US Patent:
2013031, Nov 21, 2013
Filed:
Jul 24, 2013
Appl. No.:
13/949889
Inventors:
Ron Cohen - Irvington NY, US
Assignee:
Acorda Therapeutics, Inc. - Ardsley NY
International Classification:
A61K 9/20, A61K 31/4409
US Classification:
514352
Abstract:
A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.
Compositions And Methods For Extended Therapy With Aminopyridines
US Patent:
2012002, Feb 2, 2012
Filed:
Feb 11, 2010
Appl. No.:
13/148231
Inventors:
Andrew R. Blight - Mahopac NY, US
Ron Cohen - Irvington NY, US
Ron Cohen - Irvington NY, US
Assignee:
ACORDA THERAPEUTICS, INC. - Hawthorne NY
International Classification:
A61K 31/4409, A61P 25/00
US Classification:
514352
Abstract:
Disclosed herein are methods and compositions related to use of aminopyridines, such as 4-aminopyridine, for use in a therapeutically effective manner for patients with a demyelinating condition, such as multiple sclerosis.
Sustained Release Aminopyridine Compositions
US Patent:
2010032, Dec 23, 2010
Filed:
Jun 25, 2010
Appl. No.:
12/824137
Inventors:
Andrew R. BLIGHT - Mahopac NY, US
Ron COHEN - Irvington NY, US
Ron COHEN - Irvington NY, US
International Classification:
A61K 31/4409, A61P 25/00
US Classification:
514352
Abstract:
A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.
Method, Apparatus And Solftware For Identifying Responders In Clinical Environment
US Patent:
2009015, Jun 11, 2009
Filed:
Sep 25, 2006
Appl. No.:
11/659456
Inventors:
Ron Cohen - Irvington NY, US
Andrew R. Blight - Mahopac NY, US
Lawrence Marinucci - White Plains NY, US
Andrew R. Blight - Mahopac NY, US
Lawrence Marinucci - White Plains NY, US
International Classification:
G06Q 50/00
US Classification:
705 3
Abstract:
A process for determining responders in clinical testing environments that involves, inter alia, detecting treatment response through the use of small numbers of measurements of randomly varying outcome variables in individual clinical trial subjects, and by analyzing the measurements in such a way as to eliminate troublesome variables, such as a spontaneous population variability.
Methods Of Using Sustained Release Aminopyridine Compositions
US Patent:
2013033, Dec 12, 2013
Filed:
Aug 12, 2013
Appl. No.:
13/965171
Inventors:
Ron Cohen - Irvington NY, US
Assignee:
ACORDA THERAPEUTICS, INC. - Ardsley NY
International Classification:
A61K 31/4409, A61K 31/44, A61K 45/06
US Classification:
424 92, 514352, 424 854, 4241331, 514 179, 514349
Abstract:
Disclosed herein are methods and compositions related to use of aminopyridines, such as fampridine, to improve impairments of patients with a demyelinating condition, such as MS.